Chimera Bioengineering: Funding, Investors & Team (Oct 2026)
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
Chimera Bioengineering has raised $7.5M across 1 funding round on record, the most recent a Grant of $7.5M announced in Apr 2022.
That round is in line with the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Chimera Bioengineering Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Chimera Bioengineering Funding Rounds
Chimera Bioengineering Founders and Leadership Team
Contact details for the Chimera Bioengineering team: 1 of 1 has an email address on file.
Start 14-day free trial →Chimera Bioengineering Funding Compared to Other Biotechnology Startups
Chimera Bioengineering's latest round of $7.5M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Chimera Bioengineering in Biotechnology and South San Francisco
Companies Similar to Chimera Bioengineering
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Chimera Bioengineering Funding FAQs
What does Chimera Bioengineering do?
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
How much funding has Chimera Bioengineering raised?
Chimera Bioengineering has raised $7.5M across 1 round on record. The most recent is a Grant of $7.5M announced in Apr 2022.
When did Chimera Bioengineering last raise funding?
Chimera Bioengineering's most recent funding round on record is a Grant of $7.5M, announced in Apr 2022.
Who is the CEO of Chimera Bioengineering?
Vlad Hogenhuis is listed as CEO at Chimera Bioengineering.
Where is Chimera Bioengineering headquartered?
Chimera Bioengineering is based in South San Francisco, California, United States.
How many employees does Chimera Bioengineering have?
Chimera Bioengineering is in the 11-50 employee band.
How does Chimera Bioengineering's funding compare to other Biotechnology startups?
Chimera Bioengineering's latest round of $7.5M is in line with the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Chimera Bioengineering Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Chimera Bioengineering is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.